This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Study finds 1.5 percent ruxolitinib cream safe, effective for teens with eczema

1.5 percent ruxolitinib cream safe, effective for teens with eczema

Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.

Lawrence F. Eichenfield, M.D., from the University of California San Diego, and colleagues assessed the and efficacy of 1.5% ruxolitinib cream versus vehicle and long-term of ruxolitinib cream among adolescents using pooled data from phase 3 studies. The analysis included 245 adolescents (aged 12 to 17 years) with AD for at least two years.

The researchers found that at week 8, substantially more patients who applied 1.5% ruxolitinib cream versus vehicle achieved Investigator's Global Assessment (IGA) (50.6 versus 14.0%), ≥75% improvement in the Eczema Area and Severity Index (60.9 versus 34.9%), and a 4-point improvement or greater in the itch numerical rating scale (52.1 versus 17.4%).

During the long-term safety period, mean trough steady-state ruxolitinib plasma concentrations at weeks 12 and 52 were 27.2 and 15.5 nM, respectively. With ruxolitinib, the percentage of patients achieving an IGA score of 0 or 1 was sustained or further increased. Application site reactions through 52 weeks occurred in 1.8% of participants applying 1.5% ruxolitinib cream at any time. No patients reported serious adverse events.

"Treatment with 1.5% ruxolitinib cream in with mild-to-moderate had anti-inflammatory and antipruritic effects comparable with those observed in the overall study population," the authors write.

The study was funded by Incyte, the manufacturer of ruxolitinib.

More information: Lawrence F. Eichenfield et al, Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies, American Journal of Clinical Dermatology (2024). DOI: 10.1007/s40257-024-00855-2

© 2024 HealthDay. All rights reserved.

Citation: Study finds 1.5 percent ruxolitinib cream safe, effective for teens with eczema (2024, June 1) retrieved 22 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Ruxolitinib cream results in greater repigmentation in vitiligo


Feedback to editors